GEMMA Biotherapeutics Secures $34 Million Seed Funding nextdigitalhealth.com

GEMMA Biotherapeutics is a new therapeutics company established by Dr. Jim Wilson, a gene therapy specialist, and has closed its seed funding at $34 million. This investment will support the company’s clinical-stage gene therapy programs and growth of operations.

Double Point Ventures, Bioluminescence Ventures, Earlybird Venture Capital, and Savanne Life Sciences equally backed the seed funding.